Recent advances in the management of peptic ulcer bleeding

Ian Beales1

  • 1Department of Gastroenterology, Norfolk and Norwich University Hospital, Norwich, UK.

F1000Research
|October 19, 2017
PubMed

Insights

Peptic ulcer bleeding management has advanced with restrictive transfusion strategies and improved risk scoring systems like Glasgow-Blatchford. New research explores pre-endoscopy erythromycin and novel endoscopic techniques for better patient outcomes.

Area of Science:

  • Gastroenterology
  • Internal Medicine
  • Emergency Medicine

Background:

  • Acute upper gastrointestinal hemorrhage from peptic ulcers causes significant morbidity, mortality, and healthcare costs.
  • Despite published guidelines, management of peptic ulcer bleeding continues to evolve with ongoing research and controversies.

Purpose of the Study:

  • To review recent advances and controversies in the management of acute upper gastrointestinal hemorrhage due to peptic ulcer bleeding.
  • To highlight new evidence on transfusion strategies, risk stratification scores, endoscopic interventions, and specific ulcer types.

Main Methods:

  • Review of recent literature and clinical studies on peptic ulcer bleeding management.
  • Analysis of evidence supporting new transfusion strategies, risk scores (Glasgow-Blatchford, AIMS65), pre-endoscopic therapies, and endoscopic techniques.
  • Evaluation of outcomes for non-Helicobacter pylori, non-NSAID ulcers.

Main Results:

  • A restrictive transfusion strategy (Hb 70-90 g/l) is supported by evidence.
  • The Glasgow-Blatchford score is optimal for predicting intervention needs and identifying low-risk patients.
  • Pre-endoscopy erythromycin and high-dose oral proton pump inhibitors (PPIs) post-infusion show benefits.
  • Haemostatic powders, over-the-scope clips, and Doppler probes offer advanced endoscopic options.
  • Non-H. pylori, non-NSAID ulcers present a growing challenge with poor prognosis.

Conclusions:

  • Recent advances improve the management of peptic ulcer bleeding, focusing on restrictive transfusion, accurate risk stratification, and enhanced endoscopic therapies.
  • Further research is needed to determine optimal management for non-H. pylori, non-NSAID bleeding ulcers, which are associated with higher rebleeding rates and poorer outcomes.

Related Concept Videos

Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
548
Peptic Ulcer Disease V: Surgical Management and Nursing Care01:25

Peptic Ulcer Disease V: Surgical Management and Nursing Care

Surgical management and nursing care are crucial in treating Peptic Ulcer Disease (PUD). Here is an organized and enhanced overview of the surgical interventions and the associated nursing care for PUD:
Surgical Interventions for Peptic Ulcer Disease
979
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
647
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.3K
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
1.5K
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
997